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ENVIRONMENTAL TOXICANTS AND THEIR EFFECT ON BONE HEALTH 
HOLLY M. BERNARD 
ABSTRACT 
 Osteoblasts and osteoclasts are crucial to maintaining bone homeostasis. 
These specialized cells rely on various environmental signals and cross talk from 
one another in order to model, remodel and repair bone. Exogenous chemicals such 
as the therapeutic drug rosiglitazone, a peroxisome proliferator activated receptor 
gamma (PPARγ) agonist, can interfere with bone-forming and bone-resorbing 
pathways, causing osteoporosis and increasing the risk of bone fracture. Evidence is 
emerging that environmental toxicants induce similar toxic endpoints in bone, both 
through PPARγ-dependent and PPARγ-independent mechanisms. To date, these 
toxicants have only ever been considered in isolation or in limited co-exposure 
studies. This comprehensive review relating these toxicants and their effect on bone 
health will help guide future studies and illuminate gaps in our knowledge. Five 
toxicant classes (organotins—mainly tributyltin; TBT, heavy metals—lead, 
cadmium, and arsenic, dioxin-like chemicals, phthalates, and perfluoroalkyl 
compounds; PFAs) were examined, with emphasis on molecular targets, osteoclast- 
and osteoblast-specific effects, animal models and epidemiological data. It was 
concluded that organotins (TBT) act via PPARγ and RXR agonism, phthalates act via 
PPARγ agonism, heavy metals act at least through ERK-mediated pathways, and 
dioxin-like chemicals act through aryl hydrocarbon receptor interaction. The 
molecular targets of PFAs remain unknown. Additional targets are still being 
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investigated. These findings emphasize the importance of co-exposures, as these 
toxicants act through diverse molecular mechanisms that may share toxic 
endpoints, making co-exposure consequences particularly severe. While the 
evidence available strongly suggests that lead, cadmium, and dioxin-like chemicals 
are negative modulators of human bone health, evidence supporting this conclusion 
for organotins, phthalates, arsenic, and PFAs is somewhat lacking. There are still 
significant gaps in our understanding that must be filled to gain a holistic 
understanding of these threats to human bone health. 
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INTRODUCTION  
 Bone appears to be a static tissue, but it is dynamic and plays diverse roles within 
the body. Under constant exposure to changing forces, bone is modeled and remodeled to 
adapt, add strength, and repair microfractures that compromise its integrity [1, 2]. Bone 
acts as a structural element to support soft tissues, provide protection for vital organs, and 
allow for mobility [1, 2]. Second, bone functions as a calcium and phosphorus store. 
Through careful orchestration, bone can release necessary minerals into the blood when 
demand is high to ensure proper function of vital tissues [2]. Two embryonic origins give 
rise to the cells crucial to maintaining the balance between bone building and breakdown: 
bone marrow mesenchymal stem cells and hematopoietic stem cells. 
 
Mesenchymal Stem Cell Lineage 
 Mesenchymal stem cells (MSCs) give rise to cells responsible for bone formation 
[3]. Osteoblasts actively form osteoid, an unmineralized bone precursor, as they build the 
bone matrix [4]. As the matrix forms, hydroxyapatite crystals are formed to create 
mature, mineralized bone [4]. Generally, osteoblasts line the outer and inner surfaces of 
the cortical and trabecular bone. When an osteoblast is not actively laying down bone 
matrix, it undergoes apoptosis or falls quiescent and becomes a bone lining cell [4]. 
Osteoblasts also modulate osteoclast activity, ensuring balance between bone formation 
and resorption [4]. A subset of cells becomes encased within lacunae in the bone matrix. 
Referred to as osteocytes, these cells are the resident cells of bone and form mesh-like 
networks via spindle-like projections (canaliculi or dendrites) [5]. These cell-cell 
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connections allow for the resident osteocytes to detect and respond to changes in the 
forces the bone is subjected to over time [6]. Through various modes of communication, 
osteocytes can control remodeling and resorption of bone to keep it functional and 
healthy [4], and loss of these functions through osteocyte death may be a factor in 
development of skeletal fragility [5]. 
 Runt-related transcription factor 2 (Runx2) is the master regulator for osteoblast 
formation [4, 7]. Perinatal lethality is observed in Runx2-/- mice, which fail to form 
osteoblasts and mature bone [8]. Moreover, heterozygous Runx2 mice exhibit skeletal 
abnormalities involving delayed calcification or decreased calcification in cranial bones 
and the clavicle [8]. These findings are consistent with the presentation of cleidocranial 
dysplasia, an autosomal dominant disease in humans characterized by abnormalities in 
bones formed via intramembranous ossification (such as the clavicle and cranial bones) 
and thought to be the result of Runx2 haploinsufficiency [4, 9]. Additionally, 
overexpression of Runx2 in adipose-derived stem cells can promote osteoblast 
differentiation [10]. Runx2 overexpression in human adipose-derived MSCs prompts 
osteogenic differentiation and promotes bone formation [11]. Constitutive overexpression 
of Runx2 in bone marrow stromal cells leads to a preferential increase in osteogenesis, 
which may be useful in healing complicated fractures, as seen in rats [12]. 
 MSCs are progenitors for a number of mature cell types, including osteoblasts and 
adipocytes [13]. Early gene expression (especially bone morphogenic proteins (BMPs) 
and Wnt signaling pathways) drives early commitment of MSCs towards 
osteoblastogenesis [14]. The Wnt pathway is an endogenous regulator of Runx2 and 
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osterix (Osx, downstream of Runx2) and promotes favorable conditions for osteoblast 
formation [15]. Upregulation of the Wnt pathway and, subsequently, of Runx2 is 
associated with a reciprocal decrease in expression of its adipogenic counterpart, 
peroxisome proliferator-activated receptor gamma (PPARγ) [15]. 
 
Hematopoietic Stem Cell Lineage 
  Hematopoietic stem cells (HPSCs) give rise to multinucleated osteoclasts, which 
are responsible for bone resorption [16]. Osteoclasts attach to bone via actin-rich 
podosomes and use a cell specialization termed the ruffled border to secrete hydrochloric 
acid and cathepsin K (a proteolytic enzyme) that break down the mineralized matrix, 
leaving a resorption pit behind [17]. Further, osteoclasts recruit osteoblasts to areas of 
resorption, providing a coupling mechanism essential for bone remodeling [18]. 
 Nuclear Factor of Activated T-Cells, Cytoplasmic 1 (NFATc1) is essential for 
osteoclast formation. Embryonic stem cells lacking NFATc1 expression will not develop 
into osteoclasts [19]. NFATc1 knockout mice are not viable, as the mutation is 
embryonic lethal [20, 21]. Osteoclast-deficient mice (Fos-/-) with adoptive transfer of 
NFATc1-/- HPSCs (a model for NFATc1 knockout that avoids embryonic lethality) 
develop osteopetrosis and lack mature osteoclasts while NFATc1 haploinsufficiency is 
sufficient for osteoclast differentiation and allows for normal bone density maintenance 
[21]. Overexpression of NFATc1 is sufficient to trigger osteoclast differentiation, even in 
the absence of receptor activator of NFκB ligand (RANKL) [19]. 
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Intercellular Communication 
 Osteoblasts communicate with osteoclasts via the RANKL/RANK (receptor 
activator of NFκB) system. When conditions favor bone resorption, osteoblasts produce 
RANKL [1]. Binding of RANK (a receptor present on osteoclasts and osteoclast 
precursors) and RANKL activates a signaling cascade that leads to NFATc1 expression 
[22, 23] and activates fusion of pre-osteoclasts to form mature osteoclasts [24]. When 
conditions favor bone formation, osteoblasts produce osteoprotegerin (OPG), which 
binds RANK without activating osteoclastic activity, effectively inhibiting osteoclast 
differentiation [25, 26]. The RANKL:OPG ratio determines whether bone is being 
formed or resorbed [27].  
 In turn, osteoclasts produce signaling molecules that stimulate osteoblastogenesis 
to couple bone resorption to bone building. Conditioned media collected from osteoclasts 
induces bone nodule formation in vitro [28, 29], even in the absence of bone-derived 
factors [28-30]. Determining the identity of these coupling factors has proven to be 
challenging. In instances of high remodeling activity, IL-6-mediated signaling seems to 
link osteoclast resorption and osteoblast formation of bone [31]. Similarly, CT-1 may be 
secreted by active osteoclasts, promoting bone formation in the vicinity of resorption 
[32]. Afamin, a chemokine, has been implicated as another potential coupling factor 
released by osteoclasts, as exposure induces preosteoblast migration [33]. 
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PPARγ 
 PPARγ is a ligand activated transcription factor that is the master regulator of 
adipogenesis in MSCs. PPARγ binds to DNA as a heterodimer with the retinoid X 
receptor (RXR) to initiate gene transcription when bound with ligand [34]. In PPARγ-
deficient mice, mature adipocytes do not form without the introduction of a retroviral 
vector containing the PPARγ gene [35]. Similarly, in chimeric mice models, adipose 
tissue derives only from the PPARγ+/+ precursor cells [36]. Expression of PPARγ in 
fibroblasts induces adipogenesis, further supporting its role as the definitive adipogenic 
factor [37]. 
 PPARγ can inhibit osteogenesis. PPARγ activation inhibits Runx2-mediated 
transcription of osteocalcin in osteoblasts [38]. PPARγ haploinsufficiency in mice is 
marked by higher bone mass in vivo [35]. Furthermore, PPARγ can regulate other 
pathways involved in osteoblast differentiation, such as Wnt pathways, providing a 
regulatory mechanism separate from its adipogenic mechanism [39].  
 Similarly, PPARγ can affect osteoclast function. Administration of a PPARγ 
agonist results in both increased bone resorption [40] and an increase in osteoclast 
number [41] in mice. PPARγ acts in concert with its downstream targets PGC1β and 
ERRα to enhance osteoclast activity and stimulate differentiation [42]. In addition, work 
in mice selectively unable to express PPARγ in osteoclasts has shown that PPARγ exerts 
its osteoclastogenic effects through regulation of c-fos expression [43]. 
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Rosiglitazone 
 Rosiglitazone (RSG) is a member of the thiazolidinedione (TZD) class of drugs 
and acts as a PPARγ agonist to treat type 2 diabetes mellitus (T2DM) [44]. Use of TZDs 
causes bone loss in older women (measured by DEXA scan) [45]. TZDs accelerate bone 
loss, hinder bone formation and increase the risk of appendicular skeletal fracture in 
women with T2DM [46]. Over a two-year period, RSG use in postmenopausal women 
with T2DM demonstrated a decrease in bone mass in the lumbar spine and trochanter of 
the femur [47], emphasizing the importance of further investigation into RSG’s effects on 
bone. 
 Numerous animal studies have demonstrated RSG’s effects on osteoblast- and 
osteoclast-specific functions. In rat calvarial osteoblasts, RSG suppresses osteoblast 
differentiation and calcification via a PPARγ-mediated pathway (PPARγ siRNA 
significantly reduced this effect) [48]. Similarly, RSG decreased Runx2 and Osx 
expression in mouse-derived bone marrow MSC culture [49]. In vivo, mice exposed to 
RSG exhibit a concomitant increase in bone marrow adipocytes and decrease in 
osteoblast number and bone formation [49]. Moreover, RSG can reduce trabecular bone 
volume [50] as well as bone mineral density, and may induce osteoblastic apoptosis as 
part of its bone homeostasis-altering mechanism [51]. In mouse-derived bone marrow 
cultures, RSG induces osteoclast differentiation, which may be associated with the ERK 
signaling pathway [52]. However, other studies on mouse-derived bone marrow cells 
have shown that RSG inhibits osteoclast differentiation in part by suppressing 
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RANK/RANKL components in both osteoblasts and osteoclasts [53] or osteoclast 
resorptive activity [50].  
 
Specific Aims 
 RSG is a well-known chemical that reduces bone quality and increases the risk of 
bone fracture in humans, indicating that bone is a target to toxicant effects. Many other 
such toxicants exist in our environment. Since bone homeostasis is controlled through 
many molecular pathways, there are numerous points at which environmental 
contaminants could interfere with signaling and tip the balance toward formation or 
resorption. Due to the prevalence of osteoporosis and morbidity associated with it 
(especially through fractures and their sequelae) [54], investigation into these 
environmental toxicants is necessary to understand their impact (if any) on bone health 
with the aim of reducing exposures wherever possible. Bearing that in mind, we explore 
the possibility that environmental contaminants can act as negative modulators of bone 
health. The aims of this literature review are to: 
 
1. Outline the environmental sources of five classes of bone-disrupting contaminants 
2. Examine current literature linking these compounds to effects on bone health 
3. Examine molecular targets of each class 
4. Discuss implications for human bone health 
5. Suggest future areas of study to form a more complete understanding of 
environmental toxicants and their effect on bone health  
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PUBLISHED STUDIES 
 The evidence supporting the hypothesis that environmental contaminants act as 
negative regulators of bone health for five classes of compounds (organotin compounds, 
heavy metals, dioxin-like compounds, phthalate esters, and perfluoroalkyl compounds) 
will be examined. Potential sources of exposure and current research linking each 
toxicant to potential effects on bone homeostasis, acting both alone and in combination, 
will be examined in animal models and in humans. 
 
Organotin Compounds 
 Organotin compounds (organotins) represent a class of organic molecules that 
contain tin, of which tributyltin (TBT) is a prime example [55]. TBT was used in anti-
fouling paints for ships in most countries until 2008 [56]. Concern over its potential 
toxicity was raised as mollusk populations declined in coastal areas where TBT 
concentrations were highest [57]. The observance of imposex, the development of male 
secondary sexual characteristics in female mollusks, lead to the study of TBT as a 
potential endocrine disruptor, paving the way for extensive studies on TBT, its molecular 
targets, and potential impact on human health [56].  
 Organotins are widely used in industrial processes, such as plastics manufacturing 
and wood processing, and in agriculture [58, 59]. Mono- and di-substituted butyltins are 
particularly prevalent in plastics manufacturing, but also serve as catalysts in other 
manufacturing processes [58]. Due to the high temperatures used during manufacturing, 
there is potential for regeneration of TBT, which can subsequently leach from products 
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such as PVC pipes supplying drinking water to homes [60]. Furthermore, organotins are 
measurable in house dust [61, 62], stemming from wallpaper and other household vinyl 
products into which organotin compounds are introduced during processing [62]. The 
presence of TBT in cooking implements, such as parchment paper, allows for transfer of 
butyltins to food during preparation [63]. Tri-substituted butyltins, due to their greater 
potency and toxicity, are used as biocides in wood and paper processes and breweries, 
while tri-substituted phenyltins are used mainly in agriculture as pesticides [58, 59]. 
Significant levels of organotin contamination were found in storm water runoff in areas 
without exposure to anti-fouling paint, confirming industrial processes as a source of 
exposure [64].  
 Historically, consumption of contaminated seafood has been the major source of 
human exposure [65, 66]. However, contact with organotins in the indoor environment 
has also contributed to human exposures in populations for which fish is not a significant 
part of the diet. The presence of organotins has been documented in human blood [67, 
68], breast milk [69], and TBT metabolites—especially dibutyltin (DBT)—have been 
found in significant concentrations in the human liver [63, 70].  
 Evidence has emerged that TBT acts as an endocrine disrupting chemical that 
promotes adipogenesis [71]. Organotins are ligands for both PPARγ, and its DNA 
binding partner, RXR [71, 72]. TBT and triphenyltin (TPT) are high potency PPARγ 
ligands (EC50=10 nM), followed by DBT [72-74]. Extensive work with 3T3-L1 murine 
preadipocytes has demonstrated that TBT induces adipocyte differentiation [71, 75-77]. 
In the presence of a PPARγ antagonist, TBT does not induce adipogenic effects, 
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supporting its PPARγ-dependent mode of action [76]. Similar adipogenic effects have 
been documented in both mouse and human adipose-derived multipotent stromal cells 
[78] as well as in mouse and human bone marrow-derived MSCs [74, 79]. Additionally, 
adipose-derived stem cells from mice who were exposed to TBT in utero demonstrated 
an increased expression of PPARγ, suggesting a predisposition to become adipocytes 
[78]. This evidence supports the classification of TBT as an obesogen: an environmental 
toxicant that promotes obesity [80].  
 Organotins suppress osteogenesis. In utero exposure to TBT and TPT suppress 
ossification in rat and mouse models [81-83]. In utero exposure to TBT in the C57BL/6J 
mouse generates MSCs that are deficient in the ability to undergo osteogenesis [78, 84]. 
In teleost scales, which model osteoblast and osteoclast activity in mammalian membrane 
bone, TBT inhibits osteoblast activity [85]. Furthermore, TBT-exposed rat calvarial 
osteoblast-like cells express lower levels of osteocalcin, a marker for osteoblast 
differentiation [81].  In mouse bone marrow-derived MSCs, TBT and TPT exposure 
cause a concomitant increase in adipogenesis and decrease in osteogenesis (bone nodule 
formation and calcium deposition), which is accompanied by an increase in PPARγ-
mediated transcription and a suppression of Runx2-mediated transcription [86, 87]. 
However, a PPARγ antagonist only partially rescues osteogenesis in the presence of TBT 
[87]. Baker et. al. demonstrated that TBT is capable of activating RXR- and liver X 
receptor (LXR)-mediated pathways [87], consistent with studies in macrophages showing 
TBT-dependent upregulation of Abca1 expression [88]. Further, they showed that 
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activation of RXR contributes to TBT’s ability to suppress osteogenesis and that 
activation of RXR alone can reduce osteogenic activity [87]. 
 Organotins may also suppress osteoclast differentiation. TBT and TPT, but not 
MBT or DBT, were shown to decrease osteoclast differentiation in the RAW236.7 cell 
line [89]. A retinoid acid receptor antagonist rescued NFATc1 RNA expression and 
RANKL-stimulated osteoclast differentiation in the presence of the organotins [89]. In 
contrast, TBT had no effect on osteoclast differentiation by bone marrow cells from 
C57BL/6J mice [90] and had no effect on osteoclast activity in teleost scales [85]. 
 TBT has the potential to interact with other environmental toxicants, such as 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in modifying bone homeostasis [90]. 
Individually, TBT and TCDD both decreased bone formation (alkaline phosphatase) and 
altered gene expression [90]. Additionally, TCDD consistently decreased osteocalcin 
expression, whereas TBT, at varying levels of exposure and time-points, either increased 
or decreased expression [90]. In combination, the two exert a synergistic inhibition of 
bone formation and an additive increase in bone resorption [90]. 
To date, no epidemiological data that relates organotins and bone health exist. 
 
Heavy Metals 
 Heavy metals constitute a wide range of elements and sources [91]. In this 
discussion, we focus on three major heavy metal-class contaminants: lead, cadmium, and 
arsenic. Due to common exposure routes [91, 92], co-exposures are of particular 
importance in our considerations for these environmental toxicants.  
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Lead 
 Exposure to lead comes from many sources. Lead is a component of ammunition 
[93], many batteries [94], cathode ray tubes [95, 96], electronics components [96] and 
lead-based paints [97, 98]. Until the 1960s, lead in the form of lead arsenate was used as 
a pesticide [99], and until the late 1970s, organic lead was used as an additive in gasoline 
[100]. Lead is released into the air and leaches into the ground water supply via mining 
operations [101, 102]. It is present in drinking water, food [91], and house dust [91, 103]. 
Lead is abundant in soil near mines [104], agricultural soil [105], and urban soil [91, 106, 
107]. It can also leach into crops grown in contaminated soil [104]. Of note, its use in the 
production of unplasticized PVC pipes may allow lead to leach into drinking water [108]. 
Major sources of soil contamination in the urban setting include coal combustion and 
traffic exhaust [107]. In addition, lead is found in ceramics and glassware that come into 
contact with food, providing an avenue for food contamination [109], and lead levels 
have been documented in dietary supplements [110]. Occupational exposure to lead is 
associated with the development of osteoporosis, emphasizing the importance of 
environmental exposure risk assessment [111]. 
 Human environmental exposure is evident. Lead levels have been documented in 
bone [112], blood [113-115], and urine [111]. Breast milk contains low levels of lead 
(correlated with bone turnover rate), providing a neonatal exposure route, with levels 
peaking at 6-8 months after delivery and highest levels found in primiparous mothers 
[113]. 
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 Lead suppresses bone formation. In vivo, lead exposure causes weaker bones 
(reduced mineral density, bone mass, mechanical properties) in rats, creating more 
favorable fracture conditions [116, 117]. Additionally, chronic low-level exposure to lead 
in adult rats causes osteopenia (decreased bone mineral density, increased osteoid and 
trabecular resorption) [118]. In case of fracture, lead can delay healing (most notably by 
delayed calcification) at environmentally relevant doses by inhibiting endochondral 
ossification progression in mice [119, 120]. Lead reduces β-catenin expression, keeping 
the bone callus in an immature cartilage state, and administration of a β-catenin agonist 
restores typical bone healing processes [120]. 
 Lead affects osteoblasts. Lead exposure in ROS 17/2.8 cells alters gene 
expression, hindering osteoblast activity (lowered ALP activity, bone Gla expression) 
[121]. Furthermore, lead inhibits osteoblast function by interfering with osteocalcin 
production, blocking the stimulating effect of 1,25-dihydroxyvitamin D3 [122]. Lead 
likely exerts its anti-osteoblastic effects via the Wnt/β-catenin signaling pathway [120, 
123], rather than through protein kinase C-related mechanisms [122]. Lead enhances Sost 
(sclerostin; inversely related to bone mineral density) expression in MC3T3-E1 cells and 
mouse-derived primary osteoblasts, which is associated with a decrease in bone nodule 
formation [123]. In vivo in mice, lead increases Sost expression, concomitant with 
elevation of Dkk1 and suppression of β-catenin expression [120]. It is thought that lead 
can act to suppress β-catenin via the TGFβ canonical signaling pathway[123], and 
administration of a β-catenin agonist partially mitigates lead’s suppressive action on 
osteogenesis [120, 123].  
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 Cytotoxicity in bone is also of concern with lead exposure. Lead specifically 
targets the calcium release-activated calcium influx (CRACI) in osteoblast-like cells with 
two main effects: partial suppression of CRACI initiation, and enhancement of lead 
uptake once CRACI is initiated [124, 125]. Lead influx triggers a rise in intracellular 
calcium concentration in ROS 17/2.8 osteoblastic cells [126] and rat-derived primary 
osteoblasts [127]. In ROS 17/2.8 cells, lead activates protein kinase C (inhibition of 
which blocks lead’s effects on calcium influx), which mediates the rise in intracellular 
calcium concentration [126]. In addition, influx of calcium may be partially caused by 
lead-mediated decrease in protein expression levels of phosphatidylcholine-specific 
phospholipase C (PC-PLC), as demonstrated in rat primary osteoblast cultures [127]. 
Decrease in PC-PLC and subsequent rise in intracellular calcium concentration may 
allow induction of the apoptotic pathway, providing a possible mechanism for lead-
induced apoptosis in osteoblasts [127]. Alternatively, lead may be able to inhibit the 
mTOR pathway, signaling for the cell to undergo macroautophagy, another form of 
programmed cell death in osteoblasts [128].  
 In contrast, very little is known about lead’s effects on osteoclast function. In 
fracture studies in mice exposed to lead, no effect on osteoclast number or activity was 
observed during the fracture healing process [119]. It has been observed that lead can 
induce the formation of osteoclast-like cells in mouse-derived bone marrow cultures, 
likely via a prostaglandin E2-mediated mechanism [129]. At present, nothing more is 
known about osteoclast-specific effects of lead exposure. 
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 Lead deposition in hard tissues is coupled with a loss in calcium and magnesium 
[130] and a reduction in body mass [116, 117]. In rats, younger age of exposure to lead 
correlates with a higher lead retention, even after cessation of exposure [131]. 
Additionally, mobilization of bone during pregnancy and lactation (from both trabecular 
and cortical stores) can be accelerated by low-level lead exposure pre-pregnancy in mice 
[132]. 
 In growing children, blood lead levels are positively correlated with bone 
resorption markers [115]. Conversely, lead exposure has been linked to higher bone 
mineral density in children [133]. In older populations, findings are more consistent. In 
older men, higher blood lead exposure is associated with lower bone mineral density in 
the hip, femoral neck [134] and lumbar spine [135], and with an increased hip fracture 
risk [136]. Similarly, older women with higher lead exposure are at greater risk for hip 
fracture [136] and other non-spinal fractures [137]. Furthermore, lower bone mineral 
density among Korean menopausal women correlates with higher lead exposure [138]. 
Studies in both white and Chinese populations have linked increased lead exposure to 
decreased bone mineral density in both men and women [111, 139]. 
 
Cadmium 
 Cadmium is ubiquitous in the environment. Cadmium is a component in batteries 
[94]—especially in rechargeable varieties [95]. It is also an important component of 
cathode ray tubes used in older televisions and computer monitors [96, 140], as well as in 
motherboards and other electronic components [96]. Further, it is used in paints [141, 
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142] and aspects of industry (metal coating, coal burning, smelting and refining of 
metals) [143]. It is released into the environment by mining operations [101]. Traceable 
levels of cadmium have been detected in soil [91], especially for agricultural use [92] and 
in soil near mines [104]. Further, cadmium is taken up into crops grown in contaminated 
soil and incorporated into the muscles of fish living in contaminated areas [104]. 
Cadmium is measurable in drinking water, food [91], and house dust [91, 103]. It is 
found in supplements, including dolomite, bonemeal, and vitamin-mineral supplements 
[110] and is present in tobacco [144, 145]. Additionally, cadmium is present in ceramics 
and glassware intended for dining, which allows for cadmium transfer to foodstuffs 
[109]. 
 Evidence of environmental cadmium exposure is abundant. Cadmium is found in 
bone of people not exposed via occupational hazards [112]. Further, cadmium levels are 
measurable in urine [146-148], blood [145, 148], and the lens of the eye [149]. 
Additionally, cadmium is found in breast milk [150, 151] and in the placenta [152]. High 
cadmium exposure is known to cause Itai-itai disease (renal dysfunction and 
osteomalacia caused by cadmium toxicity), prompting further investigation into 
cadmium-induced effects at various levels of exposure [153]. 
 Cadmium induces bone microstructure damage, preferentially affecting trabeculae 
(decreased trabecular thickness, number; increased dissociated trabecular ends) [154]. 
Furthermore, cessation of exposure did not reverse cadmium-induced damage to bone 
structure [155]. There is a correlation between increasing cadmium body burden, 
decreasing bone mineral density, and increasing bone resorption in rats [156-158].  
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 Cadmium exposure increases the risk for development of osteopenia, 
osteoporosis, and fracture. In female rats, all experimental animals exhibited osteopenia 
or osteoporosis after low-level chronic cadmium exposure concomitant with an increased 
risk for femoral neck fracture [159]. In contrast, male rats chronically exposed to 
cadmium exhibit only a slight risk of bone demineralization, suggesting that males are 
less vulnerable to cadmium exposure than females [156]. Additionally, early life 
exposure may enhance the risk of fractures and low bone mineral density in adulthood, as 
demonstrated in rats [157]. In ovariectomized female rats (a model for osteoporosis in 
humans), cadmium has a significant impact on bone (decrease in displacement, energy, 
strength, stress, strain and toughness of femur), while low-level exposure in non-
osteoporotic female rats had no effect on bone parameters [160]. Similarly, in 
ovariectomized cynomolgus monkeys, exposure to cadmium decreased bone mineral 
density, thinned cortical femoral bone, and increased osteoid presence [161].  
 Cadmium alters activity (lowered ALP expression) in osteoblastic MC3T3-E1 
cells [162], human Saos-2 cells (decrease in osteopontin, ALP expression) [163] and in 
rats (strong RANKL expression, weak OPG) [164], though it has no apparent effect on 
osteoblasts in teleost scales following acute exposure [85, 165]. In MC3T3-E1 cells, 
cadmium inhibits osteoclast activity in the presence of 1,25-dihydroxy vitamin D3 [162]. 
However, no association between 1,25-dihydroxy vitamin D3 and cadmium body burden 
(measured as urinary cadmium and blood cadmium levels) has been found in humans 
[148]. Cadmium induces oxidative stress in rats in conjunction with changes in bone 
(especially trabecular), which may be involved in the mechanism of cadmium skeletal 
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damage [166]. As demonstrated in rat-derived bone marrow MSCs, cadmium suppresses 
endochondral bone formation by inhibiting both osteoblast function and calcium salt 
deposition [167]. In rats, cadmium changes the gene expression profile in bone, including 
upregulation of Ssp1, a gene involved in non-collagenous bone matrix formation [168]. 
Furthermore, an ERK inhibitor blocks cadmium’s effects on osteoblast function, 
suggesting that ERK signaling mediates cadmium’s osteoblast-specific effects, including 
an upregulation of sclerostin (a bone formation inhibitor) [163]. After long-term exposure 
to cadmium in teleost scales, ER and IGF-1 expression, which participate in 
osteoblastogenesis, are lowered, providing a possible mechanism for osteoblast toxicity 
[165]. 
 Cadmium is cytotoxic to human MG-63 cells [169], Saos-2 cells [170], and 
mouse MC3T3-E1 cells [171]. As demonstrated in primary rat osteoblasts, cadmium-
induced apoptosis may be mediated by activation of the calcium-calmodulin signaling 
pathway, and use of a calmodulin antagonist halts the release of mitochondrial pro-
apoptotic factors [172].  
 Cadmium decreases osteoclast activity in teleost scales (decreased TRAP activity) 
[85, 165] and TRAP-positive multinucleated mouse cells [162]. Conversely, cadmium 
has been found to enhance osteoclast activity in canine osteoclast-like cells (in presence 
of a bone wafer), in rat osteoclasts (increased resorption area and area per osteoclast) 
[173], and in duck embryonic osteoclasts (increased f-actin rings) [174]. Furthermore, 
cadmium stimulates osteoclast differentiation in the canine, rat (increased number of 
multinucleated cells, resorption activity) [173] and duck (TRAP-positive stain, resorption 
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activity) models described above [174], as well as in mouse-derived parietal bone cell 
culture [175], in vivo in rats [164], and in RAW264.7 cells in the presence of RANKL 
(TRAP-positive cells, increased TRAP activity) [176] and osteoblasts (increased Tracp5b 
expression, TRAP staining, RANKL expression) [177]. Cadmium induces microstructure 
damage (decreased bone mineral density, trabecular number and thickness) through an 
osteoclast-mediated mechanism in rats (increased Tracp5b expression, number of 
osteoclasts) [164]. In RAW264.7 cells, cadmium induces increased expression of RANK, 
TRAF6, Fra1, c-Src and c-Fos concomitantly with increasing osteoclastic activity, 
suggesting that the osteoblast-mediated RANKL/RANK interaction may be involved in 
cadmium-mediated osteoclast modification [176, 177]. In mice, the bone remodeling 
action of cadmium requires c-Src expression, but acts independently of c-Fos [178]. 
Cadmium exposure studies across three strains of mice suggest that cadmium 
stimulates resorption (osteoclast activation) via a MAPK-mediated pathway [179].  
 There is a clear association between increasing cadmium body burden and 
decreasing bone mineral density (especially in current smokers [145, 147, 180]), and with 
increasing bone resorption in humans [148, 181]. In women, cadmium affects both the 
distal (more trabecular) and proximal (more cortical) aspects of forearm bones, lowering 
the proximal forearm bone density in younger women exposed to higher levels of 
cadmium and the distal forearm bone density of older women with higher exposure levels 
[146]. Higher levels of cadmium biomarkers are a risk factor for hip fracture [182]. Even 
women with low-level urinary cadmium are at increased risk for developing osteoporosis 
[183, 184]. Although smoking raises blood cadmium levels to three times those of non-
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smoking women [145, 181], smoking does not have any significant correlation with 
osteoporosis risk (based on hip bone mineral density measurements) [183]. In older men, 
increasing cadmium exposure is associated with decreased bone mineral density [136, 
185] and an increased risk for nonvertebral osteoporosis-associated fractures [185]. More 
alarming, urinary cadmium levels in elementary school children show a correlation with 
increased bone resorption (increased urinary DPD, urinary calcium) [186], although a 
similar study using blood cadmium as a biomarker found no correlation between 
cadmium and increased bone resorption in young children [187]. 
 
Arsenic 
 Arsenic is a ubiquitous heavy metal. A naturally occurring element in some rocks 
and soils, it can contaminate ground water that is used for drinking, crop irrigation, and 
cooking [188]. Contaminated drinking water and the food it comes into contact with is 
the major route of human exposure to arsenic [189]. It is released into the air and can 
leach into ground water from mines, even after active mining has stopped [190], and can 
be released into the air via the burning of arsenic-rich coal [191] or smelting [192, 193]. 
Arsenic is used in many aspects of industry, including pesticides and fertilizers, wood 
preservatives, as an essential element in some animal feeds, and in paint manufacturing 
[192]. Arsenic-containing crystals are used in many technological components, such as 
semiconductors, transistors, and light emitting diodes [192]. Arsenic is present in 
agricultural soil [91, 92, 104] and in crops grown from contaminated soil [104] and other 
food sources [91]. Further, arsenic is found in drinking water [91], and in the muscle of 
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fish living in contaminated areas [104]. It is also present in house dust, providing a non-
agricultural exposure route [91]. 
 Evidence of human body burden is abundant. Arsenic has been found in urine 
[194-196], blood [197], hair [197, 198], toenails [198, 199], and in trabecular, cortical, 
and joint surface bone [200]. Further, it is found in low concentrations in breast milk 
[201], and can cross the placenta to affect fetuses [202, 203].  
 Arsenic has a negative effect on bone. In vivo, arsenic exposure leads to 
microstructure damage (decreased bone mineral density, thickness, and bone 
volume/total volume ratio in trabecular bone; decreased bone mineral density, area, and 
thickness in cortical bone) [204], decreased body length, weight, and femur length [205], 
and decreased bone mineral density in rats [204, 205]. Furthermore, extremely low levels 
of arsenic exposure can inhibit endochondral ossification (growth plate cartilage fusion to 
trabeculae) [206]. In utero exposure to arsenic targets paraxial mesoderm (which 
eventually develops into skeletal elements), causing neural tube closure defects and other 
axial skeletal disorders in hamsters [207]. 
 Osteoblast-specific effects of arsenic exposure have been investigated. Arsenic 
exposure reduces osteoblast activity (lowered Alp, Runx2, and Osx, expression, lower 
calcification observed) in rat primary osteoblasts [205]. Of note, arsenic can have dual 
effects depending on the dose administered. At higher doses, arsenic promotes apoptotic 
mechanisms (increasing Bax/Bcl-2 ratio), reducing viability, but at low doses, arsenic 
supports osteoblast proliferation (promoting collagen secretion, upregulation of TGFβ 
and p-AKT) in human osteoblast-like cells [208]. In rat-derived bone marrow MSCs, 
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low-dose arsenic exposure inhibits osteoblast differentiation via an ERK-dependent 
signaling pathway (lowered BMP2, osteocalcin, Runx2; ERK inhibitor reverses these 
effects) [204].  
 Arsenic exposure induces oxidative stress and apoptosis. Arsenic activates Nrf2 
(nuclear factor (erythroid-derived 2)-like 2; controls oxidative stress-induced proteins) 
in MC3T3-E1 cells [209] and rat primary osteoblasts [205]. Further, arsenic induces 
apoptosis in human MG-63 cells [210, 211], MC3T3-E1 cells, human FOBs, mouse bone 
marrow stromal cells [211], murine embryonic maxillary mesenchymal cells [212], and 
rat-derived bone marrow MSCs [213]. In all of the aforementioned cell cultures, arsenic-
induced apoptosis is mediated via disruption of the mitochondrial membrane potential 
and increased caspase activity [211-213]. Arsenic-mediated oxidative injury alters the 
Bax/Bcl-2 ratio, as demonstrated in murine maxillary mesenchymal cells [212], MC3T3-
E1 cells, human FOB cells, human MG-63 cells [211] and human bone marrow MSCs 
[214]. Furthermore, arsenic increases GRP78 (glucose-regulating protein 78) and calpain 
(calcium-dependent cysteine protease) expression, inducing endoplasmic reticulum-
mediated apoptosis [211]. 
 In contrast, relatively little is known about arsenic’s osteoclast-specific effects. In 
RAW264.7 cells, arsenic induces hydrogen peroxide-mediated osteoclast differentiation 
(increase in TRAP-positive cells, hydrogen peroxide production) that can be inhibited by 
catalase administration [215]. Arsenic exposure decreases the number of TRAP-positive 
cells expressed in vivo in rats [205]. 
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 Human epidemiological studies on arsenic’s bone-specific effects are lacking. 
Correlations between occupational exposure (air exposure from copper smelting) and 
cancers, including bone cancer, have been documented [193], and high levels of arsenic 
exposure (in dental procedures) can lead to osteolysis of the jaw bones [216, 217], but 
low level exposure risks to bone health are not well understood. It may cause osteopenia 
in men, as men chronically exposed to arsenic have a higher occurrence of both 
osteopenia and osteoporosis when compared to men with low or no suspected exposure 
[218]. Conversely, in postmenopausal women with biomarkers indicative of recent 
arsenic exposure, no correlation was found between exposure and incidence of 
osteoporosis [196]. 
 
Interactive Effects 
 Exposure is not often limited to a single contaminant, especially among heavy 
metals. Co-exposure to cadmium and lead can reduce lead levels stored in hard tissues in 
rats, but concomitantly lowers iron and zinc levels as well [219]. Furthermore, cadmium 
and lead work in concert to decrease bone mineral density and induce microstructure 
damage to bone (especially trabecular; decreased trabecular thickness with trabecular 
fractures; decreased cortical density) and supporting tissues (marrow cavity, collagen 
fibers, osteoblasts), increasing osteoporotic risk [220]. However, while blood lead levels 
are negatively correlated with weight and height and positively with bone resorption 
markers in human co-exposure, cadmium has no significant correlation with these 
parameters [115]. Simultaneous exposure to arsenic, cadmium, and lead exhibits 
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synergistic deleterious effects on rat calvarial osteoblasts (sharp increase in radical 
oxygen species, decrease in bone nodule formation) [105]. 
 Fluoride enhances deposited lead levels in hard tissues when compared to simple 
lead exposure in rats [221]. While fluoride can reverse cadmium’s effects on bone 
mineral density in the vertebral column in rats, co-exposure results in lower mechanical 
properties and increased trabecular structural damage in the appendicular skeleton than in 
single exposures to either element [158]. Arsenic and fluoride have antagonistic effects 
on expression levels of Runx2 in rats [222] and on ODF (osteoblast differentiation factor, 
RANKL) in rat-derived osteoblast cells [223]. In addition, fluoride and arsenic act 
synergistically on OPG expression in rat osteoblasts, and varying the combined doses of 
each factor has the ability to either enhance or inhibit osteoclast activity by determining 
the RANKL to OPG ratio [223].  
 Ethanol is a more potent inhibitor of bone growth (decreased osteocalcin, PINP, 
OPG) than lead alone, and in combination, the two increase bone resorption (CTX, serum 
RANKL), skewing homeostasis toward demineralization [224]. Conversely, ethanol 
consumption lowers cadmium load in the femur in rats, most likely due in part to lower 
absorption in the intestine and increased urinary excretion of the metal [225]. Exposure to 
lead at high altitude can increase risk of mandibular disease in growing rats, suggesting 
dental health may be vulnerable in children living under these exposure conditions [226]. 
 Zinc deficiency enhances bone lead deposition, but supplemental zinc can protect 
against lead deposition at the expense of bone mineral density [227]. Similarly, zinc has 
the ability to prevent cadmium toxicity in both osteoclasts and osteoblasts in MC3T3-E1 
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cells [162], and hormone replacement therapy among postmenopausal women is 
protective against cadmium-induced bone loss [181]. Additionally, exposure to iron [228] 
or selenium [229] before or in conjunction with arsenic exposure can reduce arsenic’s 
cytotoxic and genotoxic effects in bone marrow in vivo in mice, as compared to arsenic 
exposure alone. Administration of garlic extract to mice can reduce chromosomal damage 
caused by arsenic exposure [230, 231], though garlic extract alone has mild clastogenic 
effects [231]. 
 
Dioxin-like Compounds 
 Dioxin-like compounds (DLCs) are a subset of persistent organic pollutants. Our 
discussion focuses mainly on TCDD and dioxin-like PCBs. Polychlorinated dibenzo-p-
dioxins (PCDDs, of which TCDD is one) are generated as byproducts during various 
processes, rather than directly for commercial use. Such processes include smelting 
(especially with copper), many incineration processes (most notably solid municipal 
waste incineration [232] and electronic waste incineration [233]), and the bleaching 
process in pulp and paper mills [234]. PCBs, on the other hand, were used in industry. 
PCBs are found in elastic sealants [235], exterior paints [236], and as a heat-resistant oil 
in transformers and capacitors [237]. In apartments where PCB-containing elastic 
sealants are used, this toxicant is detectable in soil, cement, and air, especially in the 
indoor environment [235]. Further, persistent organic pollutants (including PCBs and 
PCDDs) have been detected in dust in houses [238-240], offices and cars [239]. PCDDs 
have been detected in soil, sediment, and in dust surrounding electronic waste recycling 
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sites [233]. The major source of human exposure to DLCs is through consumption of 
fatty foods, including fish and shellfish [241]. Further, DLCs are found in free-range 
chicken eggs [242], fish [243], and in some meat and meat products [244]. 
 Evidence of human body burden is plentiful. Dioxins have been detected in 
human hair [245], blood [246-248], and semen [246]. In addition, dioxins readily 
accumulate in human breast milk [249, 250] and can cross the placenta [251]. Though 
PCBs are no longer used in industry, PCB levels are measurable in blood, even in 
younger individuals, attributed mainly to fish consumption and other dietary exposures 
[252]. 
 Exposure to TCDD in utero results in fetal skeletal malformations [253, 254], and 
attenuation of bone maturation (decreased mineralization) in rats [255]. Further, it has 
been linked to suppression of palatal osteogenesis, leading to the development of cleft 
palate [256]. TCDD exposure via lactation has been linked to decreased bone length, 
cross-sectional cortex area, bone mineral density, and reduced stiffness in rats, with 
earlier exposure resulting in more serious defects [257]. It interferes with growth, 
modeling, and the mechanical properties of rat bone [258]. In mice, exposure results in a 
thinner, more porous cortical region, harder bone matrix, and trabecular bone that is more 
compact [259]. Similar reductions in trabecular bone area and increases in bone mineral 
density have been observed in male rats [260]. Gender-specific differences are seen in 
rhesus monkeys exposed to low doses of TCDD, with males having more fragile bones 
while females exhibit an increase in trabecular bone mineralization and increase in total 
bone mineral density [261]. Interestingly, most defects can be reversed with long enough 
 27 
cessation of exposure in rat pups exposed during lactation [257] and in those recovering 
from spinal fusion procedures [262]. 
 Exposure to dioxin-like PCBs has been less investigated. Exposure to a mixture of 
both dioxin-like and non-dioxin-like PCBs causes asymmetrical variances in wing bone 
length in European shag chicks [263] and a decreased survival rate and developmental 
skeletal deficits in zebrafish embryos [264]. Exposure to dioxin-like PCB-126 decreases 
vertebral skeletal mineralization and increases trabecular bone density in rats [265]. 
These effects appear to be estrogen-dependent, as ovariectomized rats exposed to PCB-
126 and an estrogen supplement have an increased trabecular bone volume, while sham 
rats exposed to PCB-126 and an estrogen supplement demonstrate a decreased trabecular 
bone volume [266]. In male rats, short-term TCDD exposure lead to decreased bone 
formation (decreased PINP expression) and increased bone resorption (increased CTX 
expression), resulting in net bone loss [260]. TCDD affects mineralization in rats 
(decrease in mature crystalline structure [260], altered crystalline structure [265], delayed 
mineralization [255]), fish (no calcification of perichondral sheath in medaka [267], 
decreased calcification in zebrafish [264]), and mice (impaired mineralization; increased 
osteoid [268]). However, perinatal exposure to PCB-126 does not alter bone composition 
in female goats, while exposure to non-dioxin-like PCB-153 did exert skeletal effects 
[269]. 
 DLCs have a clear inhibitory effect on osteoblasts. Exposure to TCDD attenuates 
proliferation in MC3T3-E1 cells [254, 270] and human Saos-2 cells [253] and 
preostoblast differentiation in MC3T3-E1 cells [270]. Further, TCDD inhibits expression 
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of IGF-2 and IGFBP-6 (normally upregulated by estradiol) in MC3T3-E1 cells [254]. 
Estradiol administration does not affect TCDD’s ability to inhibit proliferation in Saos-2 
human osteoblastic cells [253]. TCDD decreases alkaline phosphatase expression, as 
demonstrated in mouse [270] and rat MSC cultures [271]. In addition, TCDD lowers 
expression of Runx2 and osteocalcin [271], further inhibiting osteoblast activity, and 
lowers osteopontin (cell adhesion protein, important in bone remodeling) expression in 
rat MSC cultures [272]. TCDD exposure in medaka (fish) downregulates osterix 
expression in axial bone structures [267]. In rat MSCs, TCDD also interferes with 
calcium deposition (deceased calcium-binding protein expression) and a number of 
proteins, the majority of which relate to c-fos and c-myc-regulated expression [273]. No 
specific in vitro studies have evaluated dioxin-like PCBs. 
 DLC’s osteoclast-specific effects remain unclear. In RAW-C3 cells, TCDD 
exposure stimulates osteoclastogenesis at low doses (up to 10 nM) [274]. Conversely, an 
earlier study using rat-derived HPSCs found that TCDD exposure reduced the number of 
mature, active osteoclasts (decreased TRAP-staining, decreased f-actin expression), 
including 1 nM and 100 nM TCDD concentration groups [271]. In primary rat bone cell 
cultures, human osteoclast cultures [275], and in mice exposed during lactation [268], 
TCDD was determined not to affect osteoclast activity. Information on in vitro 
osteoclast-specific dioxin-like PCB effects has yet to emerge. 
 The aryl hydrocarbon receptor (AHR) plays a pivotal role in DLC-mediated 
effects on bone. In vivo in mice, AHR is expressed in both osteoblasts and osteoclasts, 
though strongest expression is seen in bone resorbing osteoclasts [275]. AHR antagonism 
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in the MC3T3-E1 model and AHR deficiency in primary bone marrow MSCs suppresses 
TCDD’s ability to modify osteoblast [270, 271]. AHR-knockout mice are protected from 
TCDD-mediated bone loss and highlight the crucial role of the AHR in generating 
TCDD-dependent effects seen in wild-type mice (weaker bones in wild-type mice than in 
AHR-knockout mice) [259]. In two strains of rats differing only in their TCDD lethal 
dose (directly related to AHR sensitivity), tibial breaking force was significantly reduced 
in the more and less sensitive groups at 17 µg/kg and 170 µg/kg, respectively [258]. 
Similarly, in a study comparing rats with mutated AHR, a TCDD resistance allele, or 
wild type sensitivity, significant effects were seen only in rats with no resistance alleles 
[257]. In rats, increased osteoclastogenesis following TCDD exposure is AHR-mediated 
via Cyp1 expression (Cyp1 knockout does not demonstrate increased osteoclastogenesis) 
[274]. Similarly, TCDD-mediated cleft palate development in mice is linked to an AHR-
dependent decrease in Runx2 expression [256].   
 The link between DLCs and negative bone effects in humans remains uncertain. 
Among the Cree women (an Inuit tribe) of Canada, increased plasma PCBs (but not total 
plasma level of DLCs) are associated with a decrease in stiffness index of the calcaneus 
[276]. Additionally, among older men, PCB-118 (a dioxin-like PCB) levels are inversely 
correlated with bone mineral density [277]. A relationship between total exposure to 
persistent organic pollutants (including DLCs) and body mass composition found that, in 
those with higher body burden (especially postmenopausal women), more fat mass 
correlates with higher bone mineral density, while more lean mass also correlates with 
higher bone mineral density [278]. In those with lower body burden (especially 
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postmenopausal women), more fat mass is associated with lower bone mineral density 
and more lean body mass is associated with higher bone mineral density [278]. Similarly, 
women who ate more than one fatty fish meal a month (an exposure route for persistent 
organochlorine compounds) had a higher incidence of osteoporotic fracture than those 
who ate one or fewer fatty fish meals a month [279]. Blood 1,2,3,4,6,7,8-
heptachlorodibenzo-p-dioxin (a relative of TCDD) levels are negatively associated with 
bone mineral density in women, though there is no such association in men [248]. 
 Conversely, several studies have found little evidence of a link between DLCs 
and bone quality. A study among the Nunavik women (an Inuit tribe) of Canada found no 
relationship between DLC or PCB plasma levels and stiffness index of the calcaneus 
[280]. In a similar study of Inuit women from Greenland, bone stiffness of the calcaneus 
was found to correlate with age, body weight, former oral contraceptive use, and current 
hormone replacement therapy use, but not with PCB serum levels [281]. Further, a study 
among Swedish men found that persistent organic pollutants had no significant effect on 
bone mineral density [282]. A positive correlation between PCB-118 serum levels and 
bone mineral density was seen in women, while a negative correlation between these 
parameters was examined among men [277]. Additionally, TCDD exposure in women 
both premenopausally and postmenopausally resulted in better bone structure than those 
not exposed [247]. 
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Phthalate Esters 
 Phthalate esters (phthalates) have a wide range of uses. Phthalates are used in the 
manufacture of plastics used for vinyl building materials, medical devices, food 
packaging, and children’s toys [283]. These plasticizers are capable of leaching out of 
products such as plastic bags used to store food items [284, 285], baby bottles [286], and 
plastic items intended for children [287]. More concerning is phthalate use in personal 
care products and cosmetics. Phthalates have been detected in body wash, shampoo, 
conditioner, facial cleansers, shaving gels, skin lotion, hair care products, toner, 
deodorant, and in creams used for lipstick, face, and eyeliner applications, as well as in 
nail polish [283] and in body and hand lotions [288]. They are added to perfumes as 
solvents or fixatives [283, 289, 290], and to baby wipes as a preservative [291]. In 
addition, phthalates are present in baby shampoos, lotions and oils, sunscreens, diaper 
creams, and powders [283]. Phthalate-contaminated food is ubiquitous [292], as is 
contaminated dust in both residential and commercial areas [293, 294]. Phthalates are 
present in drinking water [295], soil [296], and air [297]. 
 Unsurprisingly, phthalate metabolites are found in human urine [298-301] and 
breast milk [302, 303].  
 Studies are just beginning to investigate the effect of phthalates on bone 
physiology. In rats, in utero exposure to diundecyl phthalate, ditridecyl phthalate [304], 
di-n-heptyl phthalate, di-n-octyl phthalate [305], di-(C(7)-C(9) alkyl) phthalate and di-
(C(9)-C(11) alkyl) phthalate [306] have all resulted in an increased incidence of lumbar 
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rudimentary ribs. In mice, in utero exposure to di(2-ethylhexyl) phthalate (and, to a lesser 
extent, di-n-butyl phthalate) result in neural tube defects and delayed ossification [307].  
 Emerging data suggest that phthalates can affect osteoblasts. In rat Py1a 
osteoblasts, benzyl butyl phthalate (BBP) exposure induces actin redistribution [308, 
309]. In particular, actin expression becomes concentrated within the nuclear envelope 
[308]. Stress fibers were also seen concentrated below the plasma membrane, altering the 
osteoblast morphology from spindle-like to rounded [309]. Rat osteoblasts exposed to 
BBP demonstrate an increase in viability (increased cyclin D3 expression, unaltered 
Bax/Bcl-2 ratio [308], unaltered p53 expression [310], no observed apoptosis [309]). 
Further, exposure to BBP and dibytul phthalate (DBP) may alter FGF-2 translocation to 
the nuclear envelope, altering downstream gene expression [311]. BBP and DBP effects 
on FGF-2 are transient [311], and changes in morphology are reversible [309]. In 
addition, co-exposure to DBP and BBP had no significant cumulative effect on FGF-2 
[311]. 
 In contrast, BBP causes negative consequences for murine osteoblasts. In 
MC3T3-E1 and mouse primary calvarial osteoblasts, exposure to DBP and BBP induced 
DNA damage and p53 expression [310]. In addition, BBP induced apoptosis and 
decreased cell viability (increased Bax/Bcl-2 ratio, increase in cytoplasmic cytochrome c, 
decreased cyclin D3 expression, number of cells in culture) [310]. Use of siRNA to 
silence p53 in MC3T3-E1 cells significantly reversed these events [310]. 
 In addition to potential apoptotic effects, phthalates can alter osteoblast 
differentiation patterns. Mono-(2-ethylhexyl) phthalate exposure in mouse bone marrow 
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MSCs results in an increase in adipogenesis (increased lipid accumulation; Fabp4 
expression) and concomitant decrease in osteogenesis (decreased ALP expression; 
decreased Osx expression) through a PPARγ-mediated mechanism [86]. 
 No literature examining phthalate exposure and osteoclast function is currently 
available. 
 In humans, there may be an association between in utero exposure to phthalates 
and lower bone age when compared to chronological age among daughters [299], though 
a similar study found no significant correlation between exposure and delayed bone 
development [300]. Phthalates increase the risk of low bone mineral density among 
postmenopausal women. Increased urinary phthalate metabolite concentration is 
negatively associated with spinal bone mineral density among this population [298]. 
Further, higher urinary phthalate metabolite concentration correlates with a lower total 
hip and femoral neck bone mineral density, increasing osteoporotic risk among 
postmenopausal women [301].  
 
Perfluoroalkyl Substances 
 Perfluoroalkyl substances (PFAs) comprise a group of environmental toxicants, 
including such chemicals as perfluorooctane carboxylic acid (PFOA), perfluorooctane 
sulfonate (PFOS) and perfluorobutane sulfonate (PFBS), which are extremely persistent 
in the environment. PFAs have been used in manufacturing since the 1940s, largely by 
3M and Dupont, and its applications include adhesives, surface protectant for fabrics, 
leathers, paper, furniture, and carpet, fire-fighting foams and lubricants that resist high 
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heat [312] as well as Teflon and non-stick cookwares [313]. Concern over PFOS and its 
negative environmental effects triggered cessation of its use in 2002, and PFBS has since 
replaced it in many commercial applications [312]. PFAs are able to enter into ground 
water (used for drinking in some communities) [314], as well as tap and bottled drinking 
water [315]. PFAs are present in food packaging [316] and can accumulate in beef [317], 
chicken eggs [318], and fish [319]. Additionally, PFAs have been measured in indoor 
dust [316, 320]. 
 PFAs have the ability to accumulate in human tissues. They have been detected in 
the lung, liver, kidney, whole bone, and brain [321] and exposure is measurable via blood 
serum samples [322, 323] and perinatal exposure via breast milk [313, 324]. 
 Limited data linking PFAs and bone toxicity in animal models are available. In 
salmon larvae exposed to PFOS or PFOA, negligible alterations in ossification were 
observed, though exposure did cause a temporary rise in Runx2 and BMP2 mRNA 
expression [325]. In vivo in mice, PFOS and PFBS can accumulate in the marrow cavity 
[326, 327], but only PFBS is capable of deposition in calcified bone itself [326].  
 No information is currently available on PFAs and their effects on osteoblasts or 
osteoclasts. 
 Limited epidemiological studies support a potential link between PFA exposure 
and negative effects on bone health. Among premenopausal women, higher PFOS serum 
concentrations correlate to a decrease in lumbar spine bone mineral density, though no 
such correlation was found when PFOA was examined [323]. Elevated serum PFOS 
levels correspond with diminished femoral neck bone mineral density in both men and 
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women and decreased total femur bone mineral density in women, while elevated serum 
PFOA levels correspond with lower total femur bone mineral density among women 
[322]. In addition, women with higher serum levels of PFOS and PFOA were more likely 
to have osteoporosis [322].  
 
Other Environmental Contaminants 
 Although this review focuses on five classes of environmental toxicants and their 
effects on bone health, many other substances are in beginning to be investigated. 
Perinatal exposure to PCB-153 (a non dioxin-like PCB) resulted in significant increase in 
trabecular bone mineral density and decrease in cross-sectional area of the metacarpal 
metaphysis, while leaving the diaphysis unaffected in female goats [269]. Higher blood 
mercury levels correlate with a lower risk of osteoporosis among postmenopausal women 
[196]. Additionally, in the marine teleost scale, exposure to both inorganic and methyl 
mercury resulted in a decrease in osteoclasts (TRAP-positive cells) [328]. In vivo in mice, 
tungsten exposure results in increased bone burden in young, but not older animals, and 
enhanced adipogenesis in the bone marrow MSCs of adult female mice [329]. In vitro 
exposure to Firemaster® 550, of which triphenylphosphate is a major component, 
activates PPARγ-dependent transcription, stimulates adipogenesis in primary mouse bone 
marrow cultures (induction of lipid accumulation; perilipin expression) and suppresses 
osteogenesis [330]. 
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CONCLUSIONS/DISCUSSION 
 Abundant evidence in animal models suggests that bone forming and bone 
resorbing cells are targets of environmental toxicants. The mechanisms of action are 
toxicant- and cell type-specific. The end result of exposures is an imbalance in bone 
formation and resorption. Human epidemiological studies that investigate associations 
between contaminant exposures and measures of bone health (e.g. bone mineral density) 
are growing and also support the conclusion that bone is a target of toxicant action in 
humans. 
 Organotins are likely negative regulators of bone homeostasis in humans, though 
the potential association between human body burden and bone health has yet to be 
examined. TBT is a PPARγ agonist whose action results in an increase in adipocyte 
differentiation and concomitant decrease in osteoblastogenesis. It is capable of 
attenuating osteoblast differentiation and reducing activity of mature osteoblasts. Further, 
osteoblasts are suppressed by TBT’s RXR- and LXR-mediated actions. Osteoclast 
alteration following organotin exposure is less certain. Retinoic acid receptor (RAR) may 
be a potential target for TBT in osteoclasts, suppressing osteoclast differentiation. Taken 
together, these data suggest that organotins suppress bone formation and may suppress 
bone resorption while increasing adipogenesis.  
 Given TBT’s propensity to generate a highly consistent anti-osteogenic, pro-
adipogenic phenotype, it is highly likely that organotins have similar effects in humans. 
Epidemiological investigation is needed before definitive conclusions can be drawn. Of 
particular concern is TBT’s ability to cross the placenta in animal models, creating a 
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predisposition for MSCs to become adipocytes [78]. If the same is true of human 
exposure, this could have major implications on lifetime osteoporotic risk and could help 
determine what, if any, action should be taken to protect developing fetuses from bone 
homeostasis-altering exposure in utero. 
 Lead has a distinct negative impact on bone health in adults, promoting fracture 
and osteoporosis. The major molecular target of lead is Sost, closely associated with its 
downstream effector, β-catenin. Lead suppresses osteoblast differentiation and activity 
while potentially stimulating osteoclast differentiation. In addition, lead may target key 
apoptotic regulators PC-PLC and mTOR in osteoblasts, enhancing its ability to halt bone 
formation by reducing the number of healthy, mature osteoblasts. These data suggest that 
lead is highly damaging to osteoblasts, thus having detrimental consequences on bone 
formation without significant alteration of osteoclast resorptive activity. Lead is an ‘equal 
opportunist’ with regard to negative bone health consequence; this is unusual, in that the 
majority of toxicants examined have gender-biased effects, most often affecting women 
more severely than men. Thus, it is especially important to limit exposure whenever 
possible. Less clear is lead’s effect on bone in children, which appears to generate a 
higher bone mineral density while simultaneously increasing bone resorption. With 
limited data suggesting lead exposure increases bone mineral density in children, further 
investigation of the adult phenotype resulting from childhood exposure is necessary to 
accurately assess childhood exposure and osteoporotic risk in later years of life. 
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 Further investigation into osteoclast-specific effects and potential cytotoxicity is 
needed before a complete understanding of lead’s bone homeostasis-altering effects can 
be achieved.  
 Like lead, cadmium negatively affects bone homeostasis. Unlike other toxicants 
examined, cadmium does not seem to alter osteoblast differentiation. Through ERK-
mediated pathways, cadmium decreases osteoblast activity, perhaps through a common 
molecular pathway with lead via enhanced Sost expression. Further, cadmium exposure 
reduces the number of osteoblasts through its pro-apoptotic mechanism while promoting 
an increase in osteoclast numbers. The majority of the evidence presented here suggests 
that cadmium increases osteoclast activity, and promotes osteoclast differentiation. The 
molecular mechanisms driving these osteoclast-specific changes are not well understood, 
though evidence suggests that c-src is an important regulator of bone remodeling effects 
seen in cadmium-exposed animal models. Thus, cadmium exerts its negative bone health 
effects not only through decreased bone formation, but also through increased resorption. 
 In women and men, cadmium exposure decreases bone mineral density and 
increases fracture risk. Of note, cadmium effects appear to be estrogen-dependent, 
presenting a greater risk for osteoporotic development among postmenopausal women, 
with much milder effects in adult men. In children, cadmium may increase bone 
resorption, though a consensus on reliable biomarkers for cadmium exposure in children 
should be reached before conclusions are drawn. Additionally, little is known about the 
consequences of childhood exposure with regard to lifelong bone health parameters.  
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 Cadmium can induce apoptosis in osteoblasts. As these molecular targets are 
relatively poorly understood, additional research is warranted to narrow in on specific 
targets within implicated pathways. 
 As with cadmium, arsenic is thought to attenuate osteogenesis and osteoblast 
activity via an ERK-mediated pathway, though research has yet to determine specific 
molecular targets within this pathway, and no connection between arsenic and Sost 
expression changes has been noted. The majority of molecular mechanism investigation 
has been focused on arsenic’s pro-apoptotic action. Arsenic induces pro-apoptotic 
conditions through Nrf2, GRP78, and calpain expression. These alterations specifically 
induce apoptosis in osteoblasts, further damaging bone forming potential. Studies within 
osteoclastic cell lines are lacking, though preliminary studies indicate an arsenic-
mediated increase in osteoclast differentiation. Further investigation is warranted to 
determine specific molecular targets creating this pro-resorptive condition. Taken 
together, data suggests that arsenic has a clear anti-osteogenic effect, created by a drop in 
bone formation in concert with increased resorptive capacity. 
 Arsenic promotes osteoporosis in men, though no correlation has been found 
between arsenic exposure and bone health in women. This conclusion is based on limited 
epidemiological data, and further investigation is warranted to either confirm or refute the 
hypothesis that arsenic preferentially effects bone health in men. 
 
Table 1. Summary of Current Toxicant Research
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Summary of current research for each toxicant, divided into osteoblast-specific effects, osteoclast-specific effects, animal 
model studies, and human epidemiological data. OB=osteoblast, OC=osteoclast, BMD=bone mineral density, 
OVX=ovariectomized
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 The majority of studies investigating arsenic-specific bone mediating effects have 
been carried out in in vitro cell cultures, making it difficult to generalize conclusions to 
animal models and human populations. Limited animal model data suggest that arsenic 
exposure is linked with deleterious bone health parameter changes, but more 
investigation is necessary before a definitive conclusion can be drawn. Based on 
extensive in vitro studies, arsenic affects osteoblasts through two mechanisms common to 
all heavy metals examined: apoptotic promotion and alteration of osteoblast activity and 
differentiation. Further investigation is needed before it can be concluded that arsenic 
exerts these effects in humans, though preliminary findings suggest that, at least in men, 
this holds true. 
 TCDD may be a regulator of bone health, though a consensus has yet to be 
reached as to whether TCDD exposure is a negative or positive regulator. TCDD acts on 
the AHR, attenuating osteoblast activity and suppressing osteoblast differentiation. In 
addition, TCDD may hinder calcium deposition and bone mineralization. Unlike many 
other toxicants under consideration, TCDD has no apparent pro-apoptotic effect in 
osteoblasts. Unfortunately, TCDD’s effects on osteoclasts are not well understood, and 
conflicting data makes it difficult to say whether TCDD enhances osteoblast function and 
differentiation, inhibits it, or has no effect on these parameters. No correlation between 
exposure and bone health parameters has been observed in men, while findings in women 
have varied, and no data on childhood exposure exist. Based on animal studies, TCDD 
may have gender-specific effects and could play a protective role in bones of female 
animals. Of note, this gender-specific effect is opposite the general trend where females 
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are more negatively affected than males. Also of interest is the reversible nature of these 
effects in animal models following cessation of exposure, though no such trend has been 
supported in humans. 
 Based on the finding that the AHR is expressed on both osteoblasts and 
osteoclasts [275], it seems likely that TCDD does affect osteoclasts, but further research 
is necessary to reach a conclusion on these specific effects. Given the data available, it is 
impossible to say if TCDD negatively regulates bone health in humans.  
 The few in vivo studies that use dioxin-like PCB specifically provide compelling 
evidence that it is a negative bone health regulator, but further research is necessary 
before these results can be generalized. 
 PCBs may or may not regulate bone health in humans. There is evidence that 
exposure to PCBs lowers bone mineral density in men, but no consensus has been 
reached among women, and no studies have investigated childhood exposure and 
possible effects. 
 Given the current lack of in vitro studies linking PCB and bone health parameters, 
it is impossible to conclude whether PCB has specific bone homeostasis-altering effects. 
Further confounding the existing data is the use of PCB mixtures in research, combining 
both dioxin-like and non dioxin-like PCBs. Given the elegant sensitivity animal models 
used to investigate AHR-mediated effects of TCDD in bone [257-259], PCB-specific, 
AHR-mediated effects would be simple to investigate. Further, more epidemiological 
evidence supporting these findings are necessary before a definitive conclusion can be 
drawn about dioxin-like PCBs and their effects on human bone health. It can only be 
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suggested that PCBs may have a negative effect on bone health, and may preferentially 
affect men. 
 Phthalates are likely negative regulators of bone formation. Phthalates can act via 
PPARγ to suppress osteoblast differentiation. Rats experience mild, reversible alterations 
in osteoblast morphology and gene expression without inducing apoptosis. In fact, cyclin 
D3 expression may account for a slight increase in osteoblast differentiation in rats [308]. 
In contrast, phthalate exposure in mice causes a pro-apoptotic state in osteoblasts, 
mediated by p53 expression. No work has been done to elucidate what, if any, effect 
phthalates have specifically on osteoclasts. 
 Emerging epidemiological evidence suggests that phthalates are negative bone 
health regulators, at least among postmenopausal women, and can cause an increase in 
osteoporotic risk. Unlike the other toxicants examined, phthalates seem to have greatly 
varying effects by species. 
 Given the apparent differences between these animal models, it is necessary to 
identify additional molecular targets in these models. Given the limited epidemiological 
data, it is likely that the mouse model is a more accurate representation of human 
phthalate-mediated effects. Though available data strongly suggests that phthalate 
exposure can inhibit bone formation, thereby negatively affecting bone homeostasis in 
humans, more research is needed to support this conclusion and identify potential 
molecular targets, especially in humans. 
 Though relatively little research is currently available regarding PFAs and their 
bone health effects, epidemiological evidence strongly suggests that PFAs are negative 
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bone health regulators in humans. At least one member of the PFA class (PFBS) is 
capable of deposition in the mineral matrix of bone [326], possibly carrying unique 
consequences for bone health. Additional studies will reveal whether or not this property 
is of importance or not. 
 Further, additional studies are needed to determine the molecular targets affected 
by this class of toxicant. To date, no work has been done in osteoblast or osteoclast 
cultures. Given the epidemiological evidence to support the negative effects of PFA on 
bone health, these studies are crucial to understanding how this toxicant class exerts its 
effects. 
 
Additional Considerations 
 Though the majority of bone health-related studies focus on osteoblasts, 
investigation into osteoclast-specific effects is just as important to understanding how 
these toxicants affect bone health. Maintaining bone homeostasis requires both properly 
functioning osteoblasts and osteoclasts, and while bone formation cannot occur without 
properly functioning osteoblasts, osteoclasts are crucial for bone remodeling, enabling it 
to adapt to and withstand new and changing demands. Without bone turnover, 
microfractures can accumulate and negatively affect bone health [331]. Thus, if we are to 
build a complete understanding of the impact of these toxicants on bone health, we must 
understand the fates of both MSCs and HPSCs. Furthermore, given their propensity for 
cross talk, the effect of toxicants on osteoblast and osteoclast interactions must also be 
considered. 
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 Similarly, identifying molecular targets is crucial. Once targets are identified, 
potential therapies can be developed with the hope of reversing detrimental effects and 
restoring bone homeostasis. In the case of heavy metals, structural alterations to the 
mineral matrix itself must also be considered, as they can deposit directly into bone itself. 
 In the quest for cell-specific molecular mechanistic data, it can be easy to lose 
sight of the larger picture. Investigation into bone health-altering effects of co-exposures 
may be more important than understanding the effects of a single toxicant in isolation 
since many toxicants share the same routes of exposure. These interactions could be 
detrimental, have no additive effect, or work together to maintain proper bone 
homeostasis. Since some co-exposures result in synergistic negative effects on bone 
health [105], it is imperative to understand these interactions, especially through 
epidemiological studies, to minimize potentially devastating interactive effects.   
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FUTURE DIRECTIONS 
 Osteoblast-specific effects have yet to be researched following PCB and PFA 
exposure. Studies examining PFBS effects on osteoblast activity and in vivo mechanical 
changes in bone would potentially yield important results concerning this recent addition 
to the PFA family and associated bone health risks. No in vitro studies are currently 
available for either of these chemicals. In addition, work separating dioxin-like PCB and 
non dioxin-like PCB effects in osteoblasts, animal models, and humans could shed light 
on which congeners of PCB mixtures are detrimental to bone health. Future studies in 
phthalate exposure should focus on work with human osteoblastic cell lines to discern 
what, if any, effect phthalates have on osteoblast activity, what potential molecular 
targets may be, and whether these potential changes more closely resemble rat or mouse 
models.  
 Information on osteoclast-specific effects in organotins, lead, arsenic, TCDD, 
PCBs, phthalates, and PFAs is currently lacking. Future studies should focus on both 
general effects (decreased osteoclast activity, number of TRAP-positive cells) and on 
potential molecular targets for these toxicants in in vitro osteoclast cell cultures. This is 
especially important with regard to lead and PFAs, which have virtually no data currently 
available. In addition, further investigation into TCDD-mediated osteoclast effects is 
needed, since the AHR is expressed in these cells and TCDD acts on this receptor. 
Likewise, phthalate-mediated effects on osteoclasts have yet to be investigated.  
 Studies comparing phthalate exposure in rodent and human models are of 
particular importance, considering the species-specific effects observed for phthalates. 
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 Cadmium’s molecular target in osteoclasts has yet to be determined, and may 
provide insight into other potential toxicant-mediated osteoclast-specific gene expression 
changes. 
 Research regarding dioxin-like PCBs should focus on determining whether or not 
the AHR is a molecular target. Given the work done with TCDD and various rat and 
mouse models, conclusions should be easy to draw about PCB exposure following 
similar protocol to that of TCDD experiments. 
 Though PFAs may not have significant effects on bone homeostasis following 
research on osteoclast- and osteoblast-specific effects, co-exposure studies are of 
particular importance. As with any of the toxicants discussed, a single exposure may not 
alter bone health significantly, but given the multitudinous mechanisms of toxicant action 
in altering bone homeostasis, co-exposure effects could be particularly severe. 
 Future epidemiological studies relating organotins, arsenic, and phthalates to bone 
health parameters are needed. In particular, no epidemiological data exists for organotins, 
making this a key deficit in our current knowledge. Though minimal data has related 
arsenic to bone health in humans, existing data has been somewhat inconclusive, 
especially following low dose exposure. Future studies should focus on low dose arsenic 
exposure and its effects on bone health. Epidemiological studies examining phthalate 
exposure have focused exclusively on postmenopausal women. Further research should 
focus on other populations, including men and premenopausal women. Additionally, 
animal models suggest that TCDD exposure may have a protective effect on bone health 
in women, but no epidemiological studies have examined TCDD exposure specifically. 
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Biomarkers for TCDD exposure should be examined as they relate to bone mineral 
density in adults to investigate whether or not TCDD has a protective effect in women.  
 Epidemiological studies examining co-exposures and subsequent bone toxicity are 
needed, especially among those toxicants that share common exposure routes. 
 Of particular importance are studies involving children. All toxicants would 
benefit from additional epidemiological studies examining the effects of childhood 
exposure both during development and in later years of life. Animal models suggest that 
early exposure may increase osteoporotic risk later in life. Long-term studies need to be 
carried out to assess childhood exposure, immediate effects on bone health, and long-
term effects on osteoporotic risk.  
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